Back to top
more

Evogene (EVGN)

(Delayed Data from NSDQ)

$2.24 USD

2.24
612,580

-0.04 (-1.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.23 -0.01 (-0.45%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Evogene (EVGN) delivered earnings and revenue surprises of 7.14% and 66.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -94.12% and 4.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 21.05% and 97.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Evogene (EVGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Compugen (CGEN) and Evogene (EVGN) have performed compared to their sector so far this year.

Bears are Losing Control Over Evogene (EVGN), Here's Why It's a 'Buy' Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Evogene (EVGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Evogene (EVGN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Evogene (EVGN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Evogene (EVGN) delivered earnings and revenue surprises of 10.53% and 15.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of 32.89% and 16.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -20.51% and 54.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 55.05% and 2,085.45%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -75% and 46.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Evogene (EVGN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Evogene (EVGN) delivered earnings and revenue surprises of 6.25% and 26.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 15.22% and 8.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Telesis Bio (TBIO) delivered earnings and revenue surprises of 2.63% and 14.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 17.78% and 7.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Evogene (EVGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evogene (EVGN) delivered earnings and revenue surprises of 66.67% and 20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 2.86% and 1.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Evogene (EVGN) Rating Upgrade to Strong Buy

by Zacks Equity Research

Evogene (EVGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Evogene (EVGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evogene (EVGN) delivered earnings and revenue surprises of 20% and 79.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -2.44% and 86.73%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of 12.50% and 94.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -425% and 98.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 19.35% and 45.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?